



Corporate Presentation

June 2019

Disclaimer

This presentation and other related materials contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, but not limited to, statements concerning: the ability of Neos Therapeutics, Inc. (“Neos”) to successfully commercialize Adzenys XR-ODT[®], Cotempla XR-ODT[®], Adzenys ER[®] (the “Approved ADHD Products”) and its generic Tussionex[®]; its ability to successfully advance its pipeline of product candidates, including licensed product candidates; its ability to maintain and protect its intellectual property; the outcome or success of its clinical trials; the rate and degree of market acceptance of its products; and its ability to develop sales and marketing capabilities. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements of this presentation are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation, Neos’ commercialization strategy for the Approved ADHD Products and other products that may be approved; the timing of such approval; Neos’ ability to market and sell the Approved ADHD Products and any other products that may be approved; Neos’ ability to successfully compete in the market for medications indicated for ADHD; the manufacture of the Approved ADHD Products or Neos’ other product candidates; the therapeutic potential of the Approved ADHD Products or Neos’ other product candidates; and other risks set forth under the caption “Risk Factors” in Neos’ most recent Annual Report on Form 10-K, as updated by Neos’ most recent Quarterly Report on Form 10-Q, and its other SEC filings. Moreover, Neos operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Neos management to predict all risks, nor can Neos assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Neos believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Neos nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Forward-looking statements in this presentation represent Neos’ views only as of the date of this presentation. Neos undertakes no obligation to update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

This presentation may contain trade names, trademarks or service marks of other companies. Neos Therapeutics does not intend the use or display of other parties’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, these other parties. Solely for convenience, the trade names, trademarks or service marks in this presentation are referred to without the symbols [®] and [™], but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.



Company Overview

- **Three marketed ADHD products with substantial growth runway**
 - Cotempla XR-ODT[®], Adzenys XR-ODT[®], Adzenys ER[®]
 - Focusing on more profitable business channels and market segments to improve net revenue per pack and accelerate TRx growth
 - Large market opportunity with >72 million prescriptions written annually for ADHD
- **Experienced specialty pharma commercial leadership and in-house salesforce**
- **Innovative, proprietary microparticle technology**
 - Technology enables development of complex modified-release PK profiles, with focus on CNS products
 - NT0502, an NCE for the treatment of sialorrhea/excessive drooling, in development; IND-enabling studies ongoing; initiation of Phase 1 clinical trial expected in 1H 2020



Product Portfolio and Development Pipeline

Product	Indication	Preclinical	Clinical	Marketed
Cotempla XR-ODT [®] (Methylphenidate)	ADHD	[Purple bar spanning Preclinical, Clinical, and Marketed stages]		
Adzenys XR-ODT [®] (Amphetamine)	ADHD	[Orange bar spanning Preclinical, Clinical, and Marketed stages]		
Adzenys-ER [®] (Amphetamine)	ADHD	[Orange bar spanning Preclinical, Clinical, and Marketed stages]		
Generic Tussionex ^{®1} (Oral Suspension)	Cough / Cold	[Dark Blue bar spanning Preclinical, Clinical, and Marketed stages]		
NT0502	Sialorrhea (Excessive Drooling)	[Light Green bar in Preclinical stage]		

¹Tussionex[®] is a registered trademark of the UCB Group of Companies



Strategic Priorities for our Business

Accelerate Path to Profitability and Position Neos for Long-term Value Creation

Realize Efficiencies

Operational productivity
and expense management

Grow ADHD Franchise

Increase net revenue per
pack and realize growth in
TRx volume

Diversify Portfolio

Advance pipeline and
expand focus beyond ADHD








ADHD

Commercial Franchise

Franchise of Once-a-Day ADHD Treatments Addresses >90% of the Market Opportunity

		
Only Long-Acting Amphetamine ODT	Amphetamine XR Oral Suspension 1.25 mg/mL	Only Long-Acting Methylphenidate ODT
<ul style="list-style-type: none">▪ Launched in Q2 2016▪ Patients 6+ years, both pediatric and adult▪ Efficacious treatment that is convenient and portable – can be taken without water▪ Anticipated exclusivity until September 2025	<ul style="list-style-type: none">▪ Launched in Q1 2018▪ Patients 6+ years, both pediatric and adult▪ Does not require refrigeration or reconstitution at pharmacy level▪ Flexible dosing allows for micro-titration	<ul style="list-style-type: none">▪ Launched in Q4 2017▪ Patients ages 6-17▪ Compelling clinical efficacy data demonstrating symptom control at 1 hour after dosing and sustained through 12 hours▪ Anticipated exclusivity until July 2026

Differentiated by Neos' Microparticle Delivery Technology



72.6 Million Prescriptions Written Annually for ADHD Medications¹



Estimated to affect 11.0% of children ages 4-17² and 4.4% of adults in the U.S.³



ADHD prescriptions grew by 2.9% in recent 12 months¹



Prescriptions for stimulant medications account for ~91% of the market¹

Drug Type	Annual Prescriptions ¹ (Million)	Annual Gross Revenue ⁴ (Billion)
Amphetamine	47.0	\$5.7
Methylphenidate	19.3	\$2.8
Non-Stimulants	6.3	\$0.3

1. IQVIA: National Prescription Audit – trailing 12 month data as of March 2019



2. 2011-2012 National Survey of Children's Health (US-DHHS) <http://www.cdc.gov/nchs/slairs/nsch.htm>. Accessed March 19, 2015.

3. Brus ML, et al. *J. Psychiatr Pract.* 2014; (6):428-37.

4. IQVIA; National Sales Perspective – trailing 12 month data as of March 2019

Commercial Strategy Focused on Net Revenue per Pack and TRx Growth

- **Salesforce aligned to high value customers – approximately 75 territories**
- **Increasing net revenue per pack**
 - 36% improvement in net revenue per pack from 1Q18 to 1Q19
- **Increasing TRx volume for ADHD portfolio**
 - 20% increase in TRx volume from 1Q18 to 1Q19



*Sales force realignment and initiation of new commercial strategy

Neos Offers “Best in ADHD Class” Patient Access Program

Neos RxConnect Program launched January 2019

- Program designed to enhance access to Neos’ ADHD medicines for commercially insured patients and healthcare providers
 - Substantially reduces patient co-pays to as low as \$0 and caps the maximum co-pay at \$50
 - Simplifies the process for filling prescriptions at participating pharmacies
- Participating pharmacies now in the vast majority of current Neos territories
- Expect to expand this program to additional pharmacies throughout 2019







Technology & Pipeline

Neos' Microparticle Technology



Active ingredient-loaded microparticles without coating are used to achieve an immediate release profile



Microparticles coated with a single polymer are used to achieve simple release profiles



Microparticles coated with multiple polymers are used to achieve more complex release profiles



Thousands of microparticles (along with required excipients) are included in each finished drug product dose




NT0502 for the Treatment of Sialorrhea

New chemical entity but active metabolite of oxybutynin, an FDA approved urology treatment



Potential expedited development and regulatory pathway

Anticholinergic agent that is preferentially selective for blocking muscarinic receptor subtypes predominant in salivary glands



Potential for reduction in saliva production and improved safety and tolerability profile

Formulation with Neos microparticle technology for once- or twice-daily dosing




Potential for enhanced PK profile and more convenient dosing for patients

**IND-enabling studies ongoing; Phase 1 study start expected in 1H 2020;
NDA submission expected in 2023**



Sialorrhea – Disease State and Market Overview

- Excessive salivation often caused by decreased intra-oral salivary clearance associated with neuromuscular dysfunction
- May lead to perioral chapping, dehydration, infection, and foul odor, as well as social embarrassment and isolation
- Neurologically impaired children and adults with Parkinson's disease, cerebral palsy, stroke, and traumatic brain injury (TBI) are commonly affected patients



Source: Mozaffarian. AHA Circulation. 2016; Taylor. MMWR Surveill Summ. 2017; Laskowitz. CRC Press;2016; Alhashemi. Neurosciences (Riyadh). 2010; Cohen. Int J Stroke. 2016; Maenner. Ann Epidemiol 2016; Marras. NPJ Parkinsons Dis. 2018; Kalf. J Neurol. 2009; Reid. Dev Med Child Neurol. 2012; McGrath Epidemiol Rev. 2008; 2015 Clozapine for Treating Schizophrenia – A comparison of the States; Maher. Ther Adv Psychopharmacol. 2016; Physician Interviews; ClearView Analysis. SCZ: Schizophrenia



Corporate Overview

Financial Overview

Fiscal Quarter Ended March 31, 2019	(in 000s)
Net Product Sales*	\$14,634
Gross Profit	\$8,238
Loss from Operations	\$(5,821)
Weighted Average Shares	49,704
Cash, Cash Equivalents & ST Investments	\$39,365



Adzenys XR-ODT

\$6.7M

Cotempla XR-ODT


\$5.8M

Generic Tussionex

\$2.0M

* FY 2018 Net Product Sales (in 000s): \$49,988

Loss from Operations



Diversifying the Neos Portfolio

Leverage Existing Commercial Infrastructure



Licensing Opportunities

Product Acquisitions




M&A Transactions

Microparticle Technology Opportunities

New Therapeutic Areas

New Molecular Entities

Partnerships



Looking Ahead

Demonstrate Operational Excellence

*Utilize analytics to optimize
decision-making*

.....

*Continue disciplined approach
to commercial investment*

Grow ADHD Franchise

*Drive increases in
net revenue per pack*

.....

*Realize growth in
TRx volume*

Diversify Business

*Advance NT0502 into Ph. 1
clinical trial in 1H 2020*

.....

*Seek licensing and
acquisition opportunities*





Corporate Presentation

June 2019